LICENSING
Project Name Therapeutic Areas Indications Stage Right Available
Anti-B7H3 ADC Oncology/Cancer Broad cancer PCC Global
BAFFR&CD3 BsAb - 01 Oncology/Cancer Blood tumor PCC Global
CCR8 mAb - 01 Oncology/Cancer Solid tumor PCC Global
CCR8 mAb - 03 Oncology/Cancer Solid tumor PCC Global
CD19 mAb - 01 Oncology/Cancer,Immunological disease Blood tumor,Autoimmune disease PCC Global
CD25 mAb - 01 Oncology/Cancer Solid tumor PCC Global
CD37/CD22 CAR-T Oncology/Cancer AML PCC Global
FRα BsAb - 01 Oncology/Cancer Solid tumor PCC Global
GDF15 mAb - 01 Oncology/Cancer Solid tumor,Cachexia PCC Global
IL10/IL10RA mAb Infectious and parasitic diseases Immunodeficiencies PCC Global
LILRB2 mAb - 01 Oncology/Cancer Solid tumor PCC Global
NF-κB inhibitor Oncology/Cancer Cancer cachexia PCC Global
OX40 mAb - 01 Immunological disease Autoimmune disease PCC Global
PD-1 VHH mAb - 01 Oncology/Cancer Solid tumors PCC Global
TIGIT&PVRIG BsAb - 01 Oncology/Cancer Solid tumors PCC Global
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Boston
|
San Jose
|
Newark
|
Frankfurt
London
|
Basel
|
Beijing
|
Shanghai
Hangzhou
|
Suzhou
Stay Connected and Get Updates
Subscribe newsletter